CN1069647C - Compound with broad-spectrum antibacterial action - Google Patents

Compound with broad-spectrum antibacterial action Download PDF

Info

Publication number
CN1069647C
CN1069647C CN98110427A CN98110427A CN1069647C CN 1069647 C CN1069647 C CN 1069647C CN 98110427 A CN98110427 A CN 98110427A CN 98110427 A CN98110427 A CN 98110427A CN 1069647 C CN1069647 C CN 1069647C
Authority
CN
China
Prior art keywords
compound
erdosteine
broad
azithromycin
trachitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN98110427A
Other languages
Chinese (zh)
Other versions
CN1246482A (en
Inventor
靳广毅
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN98110427A priority Critical patent/CN1069647C/en
Publication of CN1246482A publication Critical patent/CN1246482A/en
Application granted granted Critical
Publication of CN1069647C publication Critical patent/CN1069647C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to a compound with a broad-spectrum antibacterial function. Macrolide antibiotic azithromycin and expectorant erdosteine are combined into double salt, and the molar ratio of a molecule is 1:2. The main clinical application of the present invention is to cure excessive phlegm type trachitis and upper respiratory tract infection. The compound can be prepared into capsules, tablets, injections, oral medicinal liquid and granules. In the compound of the present invention, erdosteine and azithromycin have coordinating antibacterial functions to cause the concentration of azithromycin in the position of trachitis to be increased. The curative effect of azithromycin to excessive phlegm type trachitis can be increased, and the administration trouble of two kinds of medicine can be reduced.

Description

A kind of compound and uses thereof with broad-spectrum antibacterial action
The present invention relates to a kind of compound and uses thereof, belong to chemical pharmacy field with broad-spectrum antibacterial action.
Broad spectrum antibiotic commonly used is in the recent period treated various inflammation, and clinical have anti-inflammatory curative effect preferably, but when treatment abundant expectoration type trachitis, because the obstruction of sticking phlegm, antimicrobial drug itself is difficult for reaching inflammation part, thereby is difficult for reaching effective treatment concentration.French Patent (FR8503679) is illustrated, a kind of salt of forming by erythromycin and Erdosteine [(±)-N-(Carboxymethylthioacetyl)-homocysteine thiolactone], curative effect to erythromycin is improved, but still have deficiency, the one, erythromycin itself is unstable to acid, with sour salify self structure is destroyed, two is that two kinds of salifiable ratios of composition do not conform to clinical medicine dose.
The objective of the invention is at the problems referred to above, invent a kind of double salt of forming by broad spectrum antibiotic Azythromycin and Erdosteine.
The present invention is achieved in that by macrolide antibiotics Azythromycin (Azithromycin) and combines generation double salt with expectorant Erdosteine [(±)-N-(Carboxymethylthioacetyl)-homocysteine thiolactone].Its structural formula is as follows: In the The compounds of this invention, the mole ratio of having divided of Azythromycin and Erdosteine is 1: 2.Its clinical main application is treatment abundant expectoration type trachitis and upper respiratory tract infection.Compound of the present invention can be made capsule, tablet, injection, oral liquid, electuary.
The present invention has in the compound of broad-spectrum antibacterial action, two bases are arranged in the Azythromycin molecule, and becoming the molecules of salt mol ratio with Erdosteine is 1: 2, and molecular weight ratio is to be equivalent to 500: 332 at 749: 498, dosage during just with clinical being used is suitable, and Azythromycin is more stable to acid.The phlegm-dispelling functions that Erdosteine is stronger in the The compounds of this invention can be coordinated with the anti-microbial effect of Azythromycin, Azythromycin is improved in the concentration at bronchitis position, both promoted and improved the curative effect of Azythromycin, can reduce the trouble of taking two kinds of medicines again abundant expectoration type trachitis.
The present invention prepares embodiment:
Embodiment 1
The 500g Azythromycin is dissolved in 2 liters the methylene dichloride, drip 332g Erdosteine and 1 liter of solution that methylene dichloride forms in 5-10 ℃, after adding, in stirring at room 30 minutes, remove methylene dichloride under reduced pressure, get the crude product of quantitative salt, get elaboration, be white crystal with 1: 1 methylene dichloride/normal hexane recrystallization.Yield 85%.
Embodiment 2
Azythromycin and the Erdosteine molecule mol ratio with 1: 2 is added in 1 liter of distilled water, is stirred to CL, Sterile Filtration gets clear liquid, with lyophilize under the clear liquid aseptic condition (20 ℃), quantitative salt crystal.Yield 100%.

Claims (2)

1, a kind of compound with broad-spectrum antibacterial action is characterized in that combining generation double salt with the expectorant Erdosteine by the macrolide antibiotics Azythromycin, and its structural formula is as follows:
The molecule mole ratio of Azythromycin and Erdosteine is 1: 2.
2, the described purposes of compound in the medicine of preparation treatment abundant expectoration type trachitis and upper respiratory tract infection of a kind of claim 1 with broad-spectrum antibacterial action.
CN98110427A 1998-08-31 1998-08-31 Compound with broad-spectrum antibacterial action Expired - Fee Related CN1069647C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN98110427A CN1069647C (en) 1998-08-31 1998-08-31 Compound with broad-spectrum antibacterial action

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN98110427A CN1069647C (en) 1998-08-31 1998-08-31 Compound with broad-spectrum antibacterial action

Publications (2)

Publication Number Publication Date
CN1246482A CN1246482A (en) 2000-03-08
CN1069647C true CN1069647C (en) 2001-08-15

Family

ID=5220475

Family Applications (1)

Application Number Title Priority Date Filing Date
CN98110427A Expired - Fee Related CN1069647C (en) 1998-08-31 1998-08-31 Compound with broad-spectrum antibacterial action

Country Status (1)

Country Link
CN (1) CN1069647C (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR057882A1 (en) 2005-11-09 2007-12-26 Novartis Ag DOUBLE ACTION COMPOUNDS OF ANGIOTENSIN RECEPTOR BLOCKERS AND NEUTRAL ENDOPEPTIDASE INHIBITORS
CN101810633B (en) * 2010-03-31 2011-12-14 湖北丝宝药业有限公司 Applications of dirithromycin to preparation of medicines for treating chronic noninfective respiratory diseases
CN105395538B (en) * 2015-12-15 2016-07-20 刘月平 A kind of pharmaceutical composition treating acute upper respiratory tract infection

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1054535A (en) * 1990-03-05 1991-09-18 吉林省农业科学院长白山生物资源研究所 Crude Extraction Process of Nutrients from Fresh Ginseng Stems and Leaves

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1054535A (en) * 1990-03-05 1991-09-18 吉林省农业科学院长白山生物资源研究所 Crude Extraction Process of Nutrients from Fresh Ginseng Stems and Leaves

Also Published As

Publication number Publication date
CN1246482A (en) 2000-03-08

Similar Documents

Publication Publication Date Title
US20030082120A1 (en) Method for reducing systemic effects of aging, effects of aging on the skin, and incidence of skin damage from sun exposure using antibiotics of the tetracycline family
US12036200B2 (en) Bismuth-thiol compositions and methods for treating wounds
EP0701449B1 (en) Process for the preparation of an oral solid dosage form containing diclofenac
CN1069647C (en) Compound with broad-spectrum antibacterial action
WO1992003135A1 (en) Pharmaceutical compositions containing 5-difluoromethoxy-2-[(3,4-dimethoxy-2-pyridyl) methylsulfinyl] benzimidazole and an anti-helicobacter agent for the treatment of gastrointestinal disorders
CN101003539A (en) Trometamol salt in compound of cillin category, and preparation method
CN102718693B (en) Carbazochrome sodium sulfonate compound and composition thereof
CN100425229C (en) Local medicine preparation containing antiinfective medicine composition and its preparing method
EP0753299A1 (en) A formulation for iron chelation and a process for preparing same
CN1223578C (en) Medical compound with antalgic, inflammation relieving and thrombocyte decoagulating actions
CN1261439C (en) Cefixime sodium pharmaceutical composition and its preparation and application
CN1030184A (en) The manufacture method of anti-inflammation medicine
CN1074667C (en) Medicine for treating wound
US3253990A (en) N-methyl glucammonium salicylate and uses therefor
CN101172108A (en) Prulifloxacin active body injection
AU3716299A (en) Use of triclosan for the treatment of helicobacter pylori infections
US3538218A (en) Pharmaceutical compositions of quinine polygalacturonate and methods for their use
CN1092655A (en) A kind of medicine for the treatment of hemorrhoid
US3452022A (en) Quinine polygalacturonate
CN1437935A (en) Method for preparing medicine for relieving cough and reducing sputum
RU1811848C (en) Method for treating patients suffering from severe shigellosis
US4273783A (en) (1-Alkyl-5-nitro-2-imidazolyl)-vinyl-glyoxal-diacetals, their preparation and their use
CA2321265A1 (en) Antibacterial compositions with synergistic effect, drugs and remedies for digestive diseases containing the same, process for the production thereof and preparations associated therewith
CN1452976A (en) Compound glucose injection with clindamycin and metronidazole
CN1616090A (en) Drugs for the treatment of radiation-induced mucosal injury, recurrent aphthous ulcers, and periodontitis

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20010815

Termination date: 20150831

EXPY Termination of patent right or utility model